Strongbridge Biopharma (NASDAQ:SBBP) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Strongbridge Biopharma (NASDAQ:SBBP) from a hold rating to a buy rating in a research report report published on Tuesday morning, Zacks.com reports. Zacks Investment Research currently has $3.50 price objective on the biotechnology company’s stock.

According to Zacks, “Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing’s syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania. “

Several other research analysts have also commented on the company. ValuEngine lowered Zosano Pharma from a buy rating to a hold rating in a research report on Wednesday, May 1st. TheStreet downgraded YRC Worldwide from a c rating to a d+ rating in a research note on Wednesday, May 15th. BidaskClub upgraded Zumiez from a hold rating to a buy rating in a research note on Friday, April 26th. Finally, Oppenheimer set a $15.00 target price on Strongbridge Biopharma and gave the company a buy rating in a research note on Tuesday, March 26th. Two research analysts have rated the stock with a sell rating and seven have issued a buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $13.07.

Shares of SBBP opened at $2.92 on Tuesday. The stock has a market cap of $155.47 million, a price-to-earnings ratio of 8.97 and a beta of 0.85. The business has a fifty day moving average price of $3.09. Strongbridge Biopharma has a twelve month low of $2.76 and a twelve month high of $6.55.

Strongbridge Biopharma (NASDAQ:SBBP) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.09. The business had revenue of $4.34 million for the quarter, compared to analyst estimates of $4.69 million. Strongbridge Biopharma had a return on equity of 79.31% and a net margin of 227.79%. Equities research analysts expect that Strongbridge Biopharma will post -1.36 earnings per share for the current fiscal year.

Institutional investors have recently made changes to their positions in the company. D. E. Shaw & Co. Inc. grew its stake in shares of Strongbridge Biopharma by 89.7% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 355,874 shares of the biotechnology company’s stock valued at $1,594,000 after acquiring an additional 168,243 shares in the last quarter. 683 Capital Management LLC grew its stake in shares of Strongbridge Biopharma by 183.2% during the fourth quarter. 683 Capital Management LLC now owns 848,700 shares of the biotechnology company’s stock valued at $3,802,000 after acquiring an additional 549,000 shares in the last quarter. Private Advisors LLC acquired a new stake in shares of Strongbridge Biopharma during the first quarter valued at about $263,000. Stifel Financial Corp acquired a new stake in shares of Strongbridge Biopharma during the fourth quarter valued at about $73,000. Finally, Oppenheimer & Co. Inc. grew its stake in shares of Strongbridge Biopharma by 90.8% during the first quarter. Oppenheimer & Co. Inc. now owns 45,448 shares of the biotechnology company’s stock valued at $226,000 after acquiring an additional 21,626 shares in the last quarter. Institutional investors own 50.12% of the company’s stock.

About Strongbridge Biopharma

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency.

See Also: How to Trade Using Analysts Ratings

Get a free copy of the Zacks research report on Strongbridge Biopharma (SBBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Strongbridge Biopharma (NASDAQ:SBBP)

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.